deucravacitinib vs Fadeucravacitinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: TYK2 · full Psoriasis pipeline

deucravacitinib · Sotyktu

Marketed by Bristol-Myers Squibb

Approved in Psoriasissmall molecule
Reliable signal

NCT03611751 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo- and active-controlled trial of 1,020 participants. Both primary clinical endpoints at week 16 were met: deucravacitinib produced significantly more participants with sPGA 0/1 and PASI 75 responses than placebo.

Next expected readout: November 2026 · NCT05570955 (registry estimate)

Reported efficacy

The Percentage of Participants With sPGA Response of 0 or 1 (At week 16); The Percentage of Participants With PASI 75 Response (At week 16): The Percentage of Participants With sPGA Response of 0 or 1 (At week 16): Arm 1: BMS-986165 55.6% (95% CI 47.4 to 63.7) vs Arm 2: Placebo 6.8% (95% CI 1 to 12.5) (met)

Result source: NCT04167462

Fadeucravacitinib

Developed by Beijing InnoCare Pharma Tech Co.

Phase 3 in Psoriasissmall molecule
Partial signal

NCT06109818 · Phase 2 · completed

The trial randomized 129 participants to two ICP-488 dose groups or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical psoriasis measure PASI 75 at Week 12, but the registry does not report whether the comparison was met.

Figures via dermatology news coverage of the sponsor's announcement; no peer-reviewed publication or registry results yet. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Percentage of subjects who achieved a PASI 75 response (a reduction of minimum 75% from baseline in PASI score) at Week 12. (Baseline up to Week 12): PASI 75 at week 12: 77.3% (6 mg) and 78.6% (9 mg) vs 11.6% (placebo); primary endpoint achieved (met)

Result source: NCT06109818

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointdeucravacitinibFadeucravacitinib
PASI 7553% vs 9.4%+43.6 vs placebowk 16 · n 511NCT03611751
9 other results
  • 58.4% vs 12.7% wk 16 · n 332 · Phase 3 · primary NCT03624127
  • 68.8% vs 8.1% wk 16 · n 144 · Phase 3 · primary NCT04167462
  • 53% vs 39.8% wk 16 · n 511 · Phase 3 · secondary NCT03611751
  • 58.4% vs 35.1% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 75% vs 6.7% 12 mg QD · wk 12 · n 44 · Phase 2 · primary NCT02931838
  • 66.7% vs 6.7% 6 mg BID · wk 12 · n 45 · Phase 2 · primary NCT02931838
  • 9.1% vs 6.7% 3 mg QOD · wk 12 · n 44 · Phase 2 · primary NCT02931838
  • 38.6% vs 6.7% 3 mg QD · wk 12 · n 44 · Phase 2 · primary NCT02931838
  • 68.9% vs 6.7% 3 mg BID · wk 12 · n 45 · Phase 2 · primary NCT02931838
—Trial running · NCT06842199
PASI 9027% vs 2.7%+24.3 vs placebowk 16 · n 511NCT03611751
2 other results
  • 35.5% vs 4.2% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 38.2% vs 1.4% wk 16 · n 144 · Phase 3 · secondary NCT04167462
—Trial running · NCT06842199
PASI 10010.2% vs 1.2%+9 vs placebowk 16 · n 511NCT03611751
2 other results
  • 14.2% vs 0.6% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 4.2% vs 0% wk 16 · n 144 · Phase 3 · secondary NCT04167462
—Trial running · NCT06842199
sPGA 0/149.5% vs 8.6%+40.9 vs placebowk 16 · n 511NCT03611751
11 other results
  • 53.6% vs 7.2% wk 16 · n 332 · Phase 3 · primary NCT03624127
  • 55.6% vs 6.8% wk 16 · n 144 · Phase 3 · primary NCT04167462
  • 49.5% vs 33.9% wk 16 · n 511 · Phase 3 · secondary NCT03611751
  • 53.6% vs 32.1% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 75% vs 6.7% 12 mg QD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • 64.4% vs 6.7% 6 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
  • 20.5% vs 6.7% 3 mg QOD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • 38.6% vs 6.7% 3 mg QD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • 75.6% vs 6.7% 3 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
  • 35.5% vs 8.2% wk 16 · n 107 · Phase 4 · secondary NCT05701995
  • 51% vs 4.3% wk 16 · n 96 · Phase 4 · secondary NCT05478499
—Trial running · NCT06842199
DLQI, change-10.2 vs -2.9−7.3 vs placebo12 mg QD · wk 12 · n 44NCT02931838
4 other results
  • -8.4 vs -2.9 6 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
  • -3.8 vs -2.9 3 mg QOD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • -6.1 vs -2.9 3 mg QD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • -9.7 vs -2.9 3 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
—Trial running · NCT06842199

PASI 75

deucravacitinib
53% vs 9.4%+43.6 vs placebowk 16 · n 511NCT03611751
9 other results
  • 58.4% vs 12.7% wk 16 · n 332 · Phase 3 · primary NCT03624127
  • 68.8% vs 8.1% wk 16 · n 144 · Phase 3 · primary NCT04167462
  • 53% vs 39.8% wk 16 · n 511 · Phase 3 · secondary NCT03611751
  • 58.4% vs 35.1% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 75% vs 6.7% 12 mg QD · wk 12 · n 44 · Phase 2 · primary NCT02931838
  • 66.7% vs 6.7% 6 mg BID · wk 12 · n 45 · Phase 2 · primary NCT02931838
  • 9.1% vs 6.7% 3 mg QOD · wk 12 · n 44 · Phase 2 · primary NCT02931838
  • 38.6% vs 6.7% 3 mg QD · wk 12 · n 44 · Phase 2 · primary NCT02931838
  • 68.9% vs 6.7% 3 mg BID · wk 12 · n 45 · Phase 2 · primary NCT02931838
Fadeucravacitinib
—Trial running · NCT06842199

PASI 90

deucravacitinib
27% vs 2.7%+24.3 vs placebowk 16 · n 511NCT03611751
2 other results
  • 35.5% vs 4.2% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 38.2% vs 1.4% wk 16 · n 144 · Phase 3 · secondary NCT04167462
Fadeucravacitinib
—Trial running · NCT06842199

PASI 100

deucravacitinib
10.2% vs 1.2%+9 vs placebowk 16 · n 511NCT03611751
2 other results
  • 14.2% vs 0.6% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 4.2% vs 0% wk 16 · n 144 · Phase 3 · secondary NCT04167462
Fadeucravacitinib
—Trial running · NCT06842199

sPGA 0/1

deucravacitinib
49.5% vs 8.6%+40.9 vs placebowk 16 · n 511NCT03611751
11 other results
  • 53.6% vs 7.2% wk 16 · n 332 · Phase 3 · primary NCT03624127
  • 55.6% vs 6.8% wk 16 · n 144 · Phase 3 · primary NCT04167462
  • 49.5% vs 33.9% wk 16 · n 511 · Phase 3 · secondary NCT03611751
  • 53.6% vs 32.1% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 75% vs 6.7% 12 mg QD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • 64.4% vs 6.7% 6 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
  • 20.5% vs 6.7% 3 mg QOD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • 38.6% vs 6.7% 3 mg QD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • 75.6% vs 6.7% 3 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
  • 35.5% vs 8.2% wk 16 · n 107 · Phase 4 · secondary NCT05701995
  • 51% vs 4.3% wk 16 · n 96 · Phase 4 · secondary NCT05478499
Fadeucravacitinib
—Trial running · NCT06842199

DLQI, change

deucravacitinib
-10.2 vs -2.9−7.3 vs placebo12 mg QD · wk 12 · n 44NCT02931838
4 other results
  • -8.4 vs -2.9 6 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
  • -3.8 vs -2.9 3 mg QOD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • -6.1 vs -2.9 3 mg QD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • -9.7 vs -2.9 3 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
Fadeucravacitinib
—Trial running · NCT06842199
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Fadeucravacitinib
PASI 75 at week 12: 77.3% (6 mg) and 78.6% (9 mg) vs 11.6% (placebo); primary endpoint achieved NCT06109818 · Phase 2 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. deucravacitinib: 4 of 4 rows · Fadeucravacitinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricdeucravacitinib
Dropout rate
0.2%BMS-986165a
NCT03611751 · Phase 3 · monotherapy
show 20 more results
—BMS-986165 (Week 0 up to Week 16)
NCT03611751 · Phase 3 · monotherapy
—BMS-986165 (Week 0 up to Week 52)
NCT03611751 · Phase 3 · monotherapy
0%BMS-986165
NCT03624127 · Phase 3 · monotherapy
—BMS-986165 Week 0 up to Week 16
NCT03624127 · Phase 3 · monotherapy
—BMS-986165 Week 0 up to Week 52
NCT03624127 · Phase 3 · monotherapy
9.6%Arm 1: BMS-986165
NCT04167462 · Phase 3 · monotherapy
—BMS-986165 Week 0 up to Week 52
NCT04167462 · Phase 3 · monotherapy
—BMS-986165 Week 16 up to Week 52
NCT04167462 · Phase 3 · monotherapy
—Active Treatment - Deucravacitinib
NCT05701995 · Phase 4 · registry result, not featured evidence
0.8%Deucravacitinib
NCT05701995 · Phase 4 · registry result, not featured evidence
—Placebo Controlled - Deucravacitin
NCT05701995 · Phase 4 · registry result, not featured evidence
—Active Treatment - Deucravacitinib
NCT05478499 · Phase 4 · registry result, not featured evidence
8.7%Deucravacitinib
NCT05478499 · Phase 4 · registry result, not featured evidence
—Placebo Controlled - Deucravacitin
NCT05478499 · Phase 4 · registry result, not featured evidence
8.1%6 mg QD
NCT03924427 · Phase 3 · registry result, not featured evidence
4.5%12 mg QD
NCT02931838 · Phase 2 · registry result, not featured evidence
13.3%6 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
6.7%3 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
18.2%3 mg QD
NCT02931838 · Phase 2 · registry result, not featured evidence
22.7%3 mg QOD
NCT02931838 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—BMS-986165a
NCT03611751 · Phase 3 · monotherapy
show 20 more results
—BMS-986165 (Week 0 up to Week 16)
NCT03611751 · Phase 3 · monotherapy
—BMS-986165 (Week 0 up to Week 52)
NCT03611751 · Phase 3 · monotherapy
—BMS-986165
NCT03624127 · Phase 3 · monotherapy
—BMS-986165 Week 0 up to Week 16
NCT03624127 · Phase 3 · monotherapy
—BMS-986165 Week 0 up to Week 52
NCT03624127 · Phase 3 · monotherapy
2.7%Arm 1: BMS-986165
NCT04167462 · Phase 3 · monotherapy
—BMS-986165 Week 0 up to Week 52
NCT04167462 · Phase 3 · monotherapy
—BMS-986165 Week 16 up to Week 52
NCT04167462 · Phase 3 · monotherapy
—Active Treatment - Deucravacitinib
NCT05701995 · Phase 4 · registry result, not featured evidence
—Deucravacitinib
NCT05701995 · Phase 4 · registry result, not featured evidence
—Placebo Controlled - Deucravacitin
NCT05701995 · Phase 4 · registry result, not featured evidence
—Active Treatment - Deucravacitinib
NCT05478499 · Phase 4 · registry result, not featured evidence
3.9%Deucravacitinib
NCT05478499 · Phase 4 · registry result, not featured evidence
—Placebo Controlled - Deucravacitin
NCT05478499 · Phase 4 · registry result, not featured evidence
5.4%6 mg QD
NCT03924427 · Phase 3 · registry result, not featured evidence
2.3%12 mg QD
NCT02931838 · Phase 2 · registry result, not featured evidence
6.7%6 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
2.2%3 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
4.5%3 mg QD
NCT02931838 · Phase 2 · registry result, not featured evidence
2.3%3 mg QOD
NCT02931838 · Phase 2 · registry result, not featured evidence
Serious AEs
—BMS-986165a
NCT03611751 · Phase 3 · monotherapy
show 20 more results
1.6%BMS-986165 (Week 0 up to Week 16)
NCT03611751 · Phase 3 · monotherapy
2.9%BMS-986165 (Week 0 up to Week 52)
NCT03611751 · Phase 3 · monotherapy
—BMS-986165
NCT03624127 · Phase 3 · monotherapy
2.1%BMS-986165 Week 0 up to Week 16
NCT03624127 · Phase 3 · monotherapy
5.8%BMS-986165 Week 0 up to Week 52
NCT03624127 · Phase 3 · monotherapy
—Arm 1: BMS-986165
NCT04167462 · Phase 3 · monotherapy
2.7%BMS-986165 Week 0 up to Week 52
NCT04167462 · Phase 3 · monotherapy
0%BMS-986165 Week 16 up to Week 52
NCT04167462 · Phase 3 · monotherapy
4.9%Active Treatment - Deucravacitinib
NCT05701995 · Phase 4 · registry result, not featured evidence
—Deucravacitinib
NCT05701995 · Phase 4 · registry result, not featured evidence
2.5%Placebo Controlled - Deucravacitin
NCT05701995 · Phase 4 · registry result, not featured evidence
4.3%Active Treatment - Deucravacitinib
NCT05478499 · Phase 4 · registry result, not featured evidence
—Deucravacitinib
NCT05478499 · Phase 4 · registry result, not featured evidence
1%Placebo Controlled - Deucravacitin
NCT05478499 · Phase 4 · registry result, not featured evidence
6.8%6 mg QD
NCT03924427 · Phase 3 · registry result, not featured evidence
0%12 mg QD
NCT02931838 · Phase 2 · registry result, not featured evidence
0%6 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
2.2%3 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
2.3%3 mg QD
NCT02931838 · Phase 2 · registry result, not featured evidence
2.3%3 mg QOD
NCT02931838 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
nasopharyngitis 10.8% (placebo 11.4%)
upper respiratory tract infection 4.9% (placebo 4.3%)
diarrhoea 4.7% (placebo 7.5%)
NCT03611751 · Phase 3 · monotherapy
show 15 more results
nasopharyngitis 16% (placebo 11.4%)
upper respiratory tract infection 8.9% (placebo 4.3%)
headache 5.4% (placebo 5.5%)
NCT03611751 · Phase 3 · monotherapy
nasopharyngitis 6.3% (placebo 4.2%)
upper respiratory tract infection 6.3% (placebo 3.6%)
headache 4.8% (placebo 3%)
NCT03624127 · Phase 3 · monotherapy
nasopharyngitis 18.1% (placebo 4.2%)
upper respiratory tract infection 9.4% (placebo 3.6%)
headache 6.6% (placebo 3%)
NCT03624127 · Phase 3 · monotherapy
upper respiratory tract infection 17.8% (placebo 18.9%)
mouth ulceration 7.5% (placebo 5.4%)
nasopharyngitis 6.8% (placebo 8.1%)
NCT04167462 · Phase 3 · monotherapy
psoriasis 11.8% (placebo 2.7%)
headache 5.9% (placebo 0%)
nasopharyngitis 5.9% (placebo 8.1%)
NCT04167462 · Phase 3 · monotherapy
covid-19 9.7% (placebo 4.1%)
upper respiratory tract infection 7.8% (placebo 2%)
nasopharyngitis 3.9% (placebo 4.1%)
NCT05701995 · Phase 4 · registry result, not featured evidence
acne 7.6% (placebo 4.1%)
nasopharyngitis 6.7% (placebo 4.1%)
covid-19 5.9% (placebo 4.1%)
NCT05701995 · Phase 4 · registry result, not featured evidence
nasopharyngitis 23.4% (placebo 17.8%)
covid-19 12.8% (placebo 8.9%)
upper respiratory tract infection 11.7% (placebo 6.7%)
NCT05478499 · Phase 4 · registry result, not featured evidence
nasopharyngitis 15.5% (placebo 17.8%)
upper respiratory tract infection 11.7% (placebo 6.7%)
acne 9.7% (placebo 2.2%)
NCT05478499 · Phase 4 · registry result, not featured evidence
6 mg QD
nasopharyngitis 31.1%
acne 9.5%
constipation 5.4%
NCT03924427 · Phase 3 · registry result, not featured evidence
12 mg QD
blood creatine phosphokinase increased 15.9% (placebo 2.2%)
acne 9.1% (placebo 0%)
diarrhoea 9.1% (placebo 4.4%)
NCT02931838 · Phase 2 · registry result, not featured evidence
6 mg BID
nasopharyngitis 15.6% (placebo 4.4%)
blood creatine phosphokinase increased 8.9% (placebo 2.2%)
upper respiratory tract infection 8.9% (placebo 2.2%)
NCT02931838 · Phase 2 · registry result, not featured evidence
3 mg BID
nasopharyngitis 11.1% (placebo 4.4%)
aphthous ulcer 6.7% (placebo 0%)
headache 6.7% (placebo 4.4%)
NCT02931838 · Phase 2 · registry result, not featured evidence
3 mg QD
nasopharyngitis 11.4% (placebo 4.4%)
headache 9.1% (placebo 4.4%)
psoriasis 6.8% (placebo 4.4%)
NCT02931838 · Phase 2 · registry result, not featured evidence
3 mg QOD
headache 9.1% (placebo 4.4%)
nausea 9.1% (placebo 4.4%)
blood immunoglobulin e increased 6.8% (placebo 2.2%)
NCT02931838 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

deucravacitinib

sPGA 0/1 75% (n=44) vs 6.7% (n=45) placebo @ 12wk12 mg QD
responder rate · % of participants
NCT02931838 · Phase 2 · registry result, not featured evidence
show 15 more results
64.4% (n=45) vs 6.7% (n=45) placebo @ 12wk6 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
20.5% (n=44) vs 6.7% (n=45) placebo @ 12wk3 mg QOD
NCT02931838 · Phase 2 · registry result, not featured evidence
38.6% (n=44) vs 6.7% (n=45) placebo @ 12wk3 mg QD
NCT02931838 · Phase 2 · registry result, not featured evidence
75.6% (n=45) vs 6.7% (n=45) placebo @ 12wk3 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
49.5% (n=511) vs 8.6% (n=255) placebo @ 16wk*
NCT03611751 · Phase 3 · monotherapy · converted to % from 253 Participants as posted
49.5% (n=511) vs 33.9% (n=254) Apremilast @ 16wk*
NCT03611751 · Phase 3 · monotherapy · converted to % from 253 Participants as posted
49.8% (n=504) vs 29.5% (n=254) Apremilast @ 24wk*
NCT03611751 · Phase 3 · monotherapy · converted to % from 251 Participants as posted
53.6% (n=332) vs 7.2% (n=166) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 178 Participants as posted
53.6% (n=332) vs 32.1% (n=168) Apremilast @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 178 Participants as posted
58.7% (n=332) vs 31% (n=168) Apremilast @ 24wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 195 Participants as posted
45.5% (n=332) vs 22.2% (n=167) Apremilast*
NCT03624127 · Phase 3 · monotherapy · converted to % from 151 Participants as posted
55.6% (n=144) vs 6.8% (n=74) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
51% (n=145) vs 52.7% (n=74) placebo @ 52wk
NCT04167462 · Phase 3 · monotherapy
35.5% (n=107) vs 8.2% (n=49) placebo @ 16wk
NCT05701995 · Phase 4 · registry result, not featured evidence
51% (n=96) vs 4.3% (n=47) placebo @ 16wk
NCT05478499 · Phase 4 · registry result, not featured evidence
PASI 75 75% (n=44) vs 6.7% (n=45) placebo @ 12wk12 mg QD
responder rate · % of participants
NCT02931838 · Phase 2 · registry result, not featured evidence
show 13 more results
66.7% (n=45) vs 6.7% (n=45) placebo @ 12wk6 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
9.1% (n=44) vs 6.7% (n=45) placebo @ 12wk3 mg QOD
NCT02931838 · Phase 2 · registry result, not featured evidence
38.6% (n=44) vs 6.7% (n=45) placebo @ 12wk3 mg QD
NCT02931838 · Phase 2 · registry result, not featured evidence
68.9% (n=45) vs 6.7% (n=45) placebo @ 12wk3 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
53% (n=511) vs 9.4% (n=255) placebo @ 16wk*
NCT03611751 · Phase 3 · monotherapy · converted to % from 271 Participants as posted
53% (n=511) vs 39.8% (n=254) Apremilast @ 16wk*
NCT03611751 · Phase 3 · monotherapy · converted to % from 271 Participants as posted
58.7% (n=504) vs 37.8% (n=254) Apremilast @ 24wk*
NCT03611751 · Phase 3 · monotherapy · converted to % from 296 Participants as posted
58.4% (n=332) vs 12.7% (n=166) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 194 Participants as posted
58.4% (n=332) vs 35.1% (n=168) Apremilast @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 194 Participants as posted
69.3% (n=332) vs 38.1% (n=168) Apremilast @ 24wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 230 Participants as posted
56.3% (n=332) vs 30.5% (n=167) Apremilast*
NCT03624127 · Phase 3 · monotherapy · converted to % from 187 Participants as posted
68.8% (n=144) vs 8.1% (n=74) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
71% (n=145) vs 70.3% (n=74) placebo @ 52wk
NCT04167462 · Phase 3 · monotherapy
PASI 90 27% (n=511) vs 2.7% (n=255) placebo @ 16wk
responder rate · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 138 Participants as posted
show 5 more results
32.5% (n=504) vs 19.7% (n=254) Apremilast @ 24wk*
NCT03611751 · Phase 3 · monotherapy · converted to % from 164 Participants as posted
35.5% (n=332) vs 4.2% (n=166) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 118 Participants as posted
42.2% (n=332) vs 22% (n=168) Apremilast @ 24wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 140 Participants as posted
31% (n=332) vs 15.6% (n=167) Apremilast*
NCT03624127 · Phase 3 · monotherapy · converted to % from 103 Participants as posted
38.2% (n=144) vs 1.4% (n=74) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
PASI 100 10.2% (n=511) vs 1.2% (n=255) placebo @ 16wk
responder rate · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 52 Participants as posted
show 2 more results
14.2% (n=332) vs 0.6% (n=166) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 47 Participants as posted
4.2% (n=144) vs 0% (n=74) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
sPGA (0 15.7% (n=511) vs 1.2% (n=255) placebo @ 16wk
responder rate · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 80 Participants as posted
show 2 more results
17.5% (n=332) vs 0.6% (n=166) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 58 Participants as posted
13.9% (n=144) vs 0% (n=74) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
PSSD Symptom -28.9 vs -4.2 placebo score @ 16wk
absolute change · score
NCT03611751 · Phase 3 · monotherapy
show 2 more results
-29.4 vs -22.8 Apremilast score @ 16wk
NCT03624127 · Phase 3 · monotherapy
-29.4 vs -1.8 placebo score @ 16wk
NCT04167462 · Phase 3 · monotherapy
PSSD Symptom Score 0 7.5% (n=466) vs 1.3% (n=238) placebo @ 16wk
event count · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 35 Participants as posted
show 1 more result
7.9% (n=305) vs 0.7% (n=149) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 24 Participants as posted
Ss-PGA 0/1 59.7% (n=305) vs 17.3% (n=173) placebo @ 16wk
responder rate · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 182 Participants as posted
show 2 more results
70.3% (n=209) vs 17.4% (n=121) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 147 Participants as posted
62.9% (n=105) vs 9.8% (n=51) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
DLQI 0/1 37.6% (n=495) vs 9.8% (n=246) placebo @ 16wk
responder rate · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 186 Participants as posted
show 2 more results
41% (n=322) vs 10.6% (n=160) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 132 Participants as posted
36.4% (n=140) vs 11.6% (n=69) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
PGA-F 0/1 20.3% (n=69) vs 7.9% (n=38) placebo @ 16wk
responder rate · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 14 Participants as posted
show 2 more results
20.9% (n=43) vs 8.8% (n=34) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 9 Participants as posted
19.6% (n=46) vs 4.2% (n=24) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
Pp-PGA 0/1 46.2% (n=39) vs 23.5% (n=17) placebo @ 16wk
responder rate · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 18 Participants as posted
show 1 more result
66.7% (n=15) vs 0% (n=7) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
Time to Relapse Median NA vs NA placebo months
time to event · months
NCT03611751 · Phase 3 · monotherapy

+ 11 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: deucravacitinib's landscape · Fadeucravacitinib's landscape